Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasms 2 Lung Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Refractory/Relapse Neuroblastoma 1 Papillomavirus Infections 1 Osteoporosis 1 Neuroendocrine Tumors 1 Neoplasms, Squamous Cell 1 Nasopharyngeal Carcinoma 1 Multiple Myeloma 1 Multiple Endocrine Neoplasia Type 1 1 Melanoma 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, B-Cell 1 Lymphoma 1 Leukemia, B-Cell 1 Kidney Neoplasms 1 Inflammatory Bowel Diseases 1 Infertility 1 Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1 Hodgkin Disease 1 High Grade Cervical Intraepithelial Neoplasia 1 Esophageal Neoplasms 1 Burkitt Lymphoma 1

Interventions

lutetium Lu 177 dotatate 40 Everolimus 35 Magnetic Resonance Spectroscopy 15 lanreotide 14 gallium Ga 68 dotatate 13 Temozolomide 13 Octreotide 12 Nivolumab 12 pembrolizumab 11 Capecitabine 11 surufatinib 10 177Lu-octreotide, DOTA(0)-Tyr(3)- 10 cabozantinib 9 Positron Emission Tomography Computed Tomography 9 3-Iodobenzylguanidine 9 Sunitinib 8 Specimen Handling 7 Carboplatin 7 telotristat ethyl 6 pasireotide 6 amino-acid, glucose, and electrolyte solution 6 Somatostatin 6 Lutetium-177 6 90Y-octreotide, DOTA-Tyr(3)- 6 lenvatinib 5 Ipilimumab 5 Ga(III)-DOTATOC 5 Fluorodeoxyglucose F18 5 Etoposide 5 Cisplatin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroendocrine Tumors × Biological Products × Clear all

NCT07366658 2026-01-26

NEUK203-13

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1 Not yet recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡